Skip to main content

Table 1 Study designs and relapse rates from several randomized withdrawal studies in patients with MDD

From: Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder

Source

Study objectives, design and analysis

Reported relapse rates

Rapaport et al. [1]

Escitalopram continuation treatment to prevent relapse; a multi-center, placebo controlled, randomized withdrawal study; 36-week randomized treatment; Kaplan-Meier estimate and log-rank test as primary statistical analysis

Escitalopram

26.0%* (109)

  

Placebo

40.0%* (116)

Keller et al. [2]

Long-term efficacy and tolerability of gepirone ER; a multi-center, placebo controlled, randomized withdrawal study; 40-44 weeks of randomized treatment; chi-square test; Kaplan-Meier estimate and log-rank test as Primary statistical analysis

Gepirone ER

20.6% (26/126)

  

Placebo

28.2% (35/124)

Kamijima et al.[3]

Efficacy, safety and tolerability of sertraline in the prevention of relapse; a multicenter, placebo controlled, randomized withdrawal study; 16-week randomized treatment; Kaplan-Meier estimate and log-rank test as primary statistical analysis

Sertraline

08.5% (10/117)

  

Placebo

19.5% (23/118)

Perahia et al. [4]

Efficacy, safety and tolerability of duloxetine in the prevention of relapse; A multi-center, placebo controlled, randomized withdrawal study; 26-week randomized treatment; Kaplan-Meier estimate, log-rank test as primary statistical analysis

Duloxetine

17.4% (23/132)

  

Placebo

28.5% (39/137)

Kocsis et al. [5]

Long-term efficacy and safety of venlafaxine ER in preventing recurrence; a multi-center, placebo controlled, randomized withdrawal study; 12 months randomized treatment; Kaplan-Meier estimate and log-rank test as primary statistical analysis

Venlafaxine ER

23.1%* (129)

  

Placebo

42.0%* (129)

  1. * Determined by a Kaplan-Meier estimate as the number of patients with relapse was not reported in the article.